Study of Immunosuppressive Therapy Toxicities in Kidney Transplant Recipients at Regional or Sate⦠(NCT00902980) | Clinical Trial Compass
CompletedNot Applicable
Study of Immunosuppressive Therapy Toxicities in Kidney Transplant Recipients at Regional or Satellite Community Clinics
Canada264 participantsStarted 2005-04
Plain-language summary
This is a multicentre, observational, non-interventional, retrospective analysis by chart review.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patient is at least 18 months post transplant
* Patient had the current transplant during the period 1 July 1997 to no less than 18 months prior to chart review
* Patient is currently on tacrolimus/MMF or AZA - or cyclosporine/MMF or AZA based immunosuppressive therapy
* Patient is not a recipient of dual kidney or multi -organ transplant
* Patient has a functioning graft (i.e. patient does not require dialysis)
* Patient is recipient of a renal transplant including living or cadaveric, related or non-related, or pediatric en bloc kidneys, but excluding kidney-pancreas transplant recipients
* Patient received the current transplant at one of six identified regional transplant centers
* Patient is currently followed in a regional or satellite community based nephrology clinic
What they're measuring
1
Change in renal function over 6-18 months estimated by change in serum creatinine and glomerular filtration rate (GFR)